ArticlePharmaceuticals (Basel, Switzerland)2021

Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars.

Ali M Alsamil et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.